Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 279 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Arginine-hydrochloride Clear all
Completed Phase 3 Interventional

A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

NCT04786873
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Macimorelin, Arginine, Clonidine
Drug · Diagnostic Test
Lead sponsor
AEterna Zentaris
Industry
Eligibility
2 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Greenwood Village, Colorado • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

NCT01262456
View directory record Official record
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Phase 1 Interventional

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

NCT01665183
View directory record Official record
Conditions
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Sep 23, 2026, 2:21 AM EDT
Terminated No phase listed Observational

Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

NCT02636387
View directory record Official record
Conditions
Nocturnal Enuresis, Anemia, Sickle Cell
Interventions
Desmopressin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
8 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels

NCT01841281
View directory record Official record
Conditions
Asthma, Inflammation
Interventions
L-Arginine, Placebo
Drug
Lead sponsor
Nicholas Kenyon
Other
Eligibility
19 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 23, 2026, 2:21 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome

NCT06635629
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Desmopressin, Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 2:21 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Oxytocin and Arginine Vasopressin in Pain Relief

NCT01328561
View directory record Official record
Conditions
Placebo Analgesia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Not applicable Interventional

Immune-modulation Effects of an Arginine Rich Nutritional Supplement in Surgical Patients

NCT01885728
View directory record Official record
Conditions
Immunity
Interventions
An arginine rich nutritional supplement
Dietary Supplement
Lead sponsor
Martin Angst
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 23, 2026, 2:21 AM EDT
Withdrawn Phase 4 Interventional

L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD

NCT01855334
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Spironolactone, L-arginine, Placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 23, 2026, 2:21 AM EDT
Recruiting Not applicable Interventional

Daily Amino Acid Supplementation for People With Parkinson's Disease

NCT07115563
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
Targeted Amino Acid Supplement, Control (placebo)
Dietary Supplement
Lead sponsor
Cristina Colon-Semenza
Other
Eligibility
50 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Farmington, Connecticut • Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing

NCT00324064
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
GHRH/arginine stimulation testing
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2010 · Synced Sep 23, 2026, 2:21 AM EDT
Completed No phase listed Observational

Gyrate Atrophy of the Choroid and Retina

NCT00001166
View directory record Official record
Conditions
Gyrate Atrophy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women

NCT01186796
View directory record Official record
Conditions
Healthy
Interventions
Fulvestrant
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Sep 23, 2026, 2:21 AM EDT
Not listed Not applicable Interventional

Study of Arginine Metabolism and Nitric Oxide Formation in Relation to Glutamine Supply in Severely Burned Patients

NCT00216970
View directory record Official record
Conditions
Burns
Interventions
Alteration in nutritional support
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Sep 23, 2026, 2:21 AM EDT
Terminated Phase 1 Interventional

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

NCT05813327
View directory record Official record
Conditions
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
Interventions
ADI PEG20, Ifosfamide, Radiotherapy, Mesna
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 23, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional Results available

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

NCT01266018
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ADI-PEG 20 (Arginine deiminase pegylated)
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Early Phase 1 Interventional

Oral Supplementation to Enhance Recovery Pilot Study

NCT03204266
View directory record Official record
Conditions
Malignant Neoplasms of Urinary Tract
Interventions
Arginine recovery supplement, Omega-3 Fatty Acids
Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Phase 2 Interventional

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

NCT05190744
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus, Congenital Nephrogenic Diabetes Insipidus
Interventions
PB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Phase 4 Interventional Results available

Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension

NCT05439460
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Phenylephrine, Epinephrine, Arginine Vasopressin
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 23, 2026, 2:21 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Sex Differences in the Vascular Effects of E-cigarette Use

NCT06159608
View directory record Official record
Conditions
E-cigarette Use
Interventions
Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor), Chronic estrogen exposure
Drug · Other
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 24 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition Interventions to Support the Immune System in Response to Stress

NCT02053506
View directory record Official record
Conditions
Mitigation of Immune Function Decrements in Response to Stress
Interventions
Immune-enhancing nutritional beverage, Probiotics (BB-12), Placebo (for nutritional beverage and probiotic)
Dietary Supplement
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 23, 2026, 2:21 AM EDT
Not listed Phase 1 Interventional

A Phase I Open-label Study for Subjects With Advanced Malignancies

NCT04136834
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
PT01 (Pegtomarginase)
Biological
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

NCT03449901
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
pegylated arginine deiminase, Gemcitabine, Docetaxel, Tumor biopsy, Research blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Palo Alto, California • Santa Monica, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 23, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients

NCT01223937
View directory record Official record
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
41
States / cities
Huntsville, Alabama • Scottsdale, Arkansas • Foothill Ranch, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 23, 2026, 2:21 AM EDT